

Francesca Giulimondi

WORK EXPERIENCE

[04/2021 – Current] Post-Doctoral researcher
prof. Giulio Caracciolo, Department of Molecular Medicine, Sapienza University of Rome

[10/2017 – 04/2021] PhD student
prof. Giulio Caracciolo, Department of Molecular Medicine, Sapienza University of Rome

[06/2019 – 08/2019] PhD Internship
prof. Hans Clevers, Hubrecht Institute, Utrecht, The Netherlands

[10/2015 – 09/2017] Student
prof. Isabella Screpanti, Department of Molecular Medicine, Sapienza University of Rome

[06/2015 – 09/2015] Student
prof. Roberto Contestabile, Department of Biochemical Sciences, Sapienza University of Rome

EDUCATION AND TRAINING

[10/2017 – 04/2021] PhD in Molecular Medicine
Sapienza University of Rome

[10/2015 – 10/2017] Master's degree Genetics and molecular biology in basic and biomedical research
Sapienza University of Rome

[10/2011 – 10/2015] Bachelor's degree Biological Sciences
Sapienza University of Rome

LANGUAGE SKILLS

Mother tongue(s): Italian

Other language(s): English

Listening B1 Reading B1 Writing B1

Spoken production B1 Spoken interaction B1

PUBLICATIONS

Number of publications= 16

h-index (Scopus)= 9

CONFERENCES AND SEMINARS

[13/04/2022-15/04/2022] 16th EUROPEAN SYMPOSIUM ON CONTROLLED DRUG DELIVERY
Egmond and Zee, The Netherlands, Poster

[27/11/2018-28/11/2018] Cell communication and signaling. How to turn bad language into positive one.
Istituto Ortopedico Rizzoli, Centro di Ricerca Codivilla Putti, Bologna

[18/10/2018] Workshop: "Discovering Organoids: The Journey Of 3D Cultures Systems"
Roma Tre University of Rome

PUBLICATIONS

1. Giulimondi F., et al., Particle & Particle Systems Characterization, (2023), 40.2: 2200169.
2. Cui L., et al., Nanoscale Advances, (2022), 4.18: 4009-4015.
3. Giulimondi F., et al., Nanoscale, (2022), 14.29: 10531-10539.
4. Giulimondi F., et al., ACS nano, (2022), 16, 2, 2088–2100
5. Quagliarini E., et al., Pharmaceutics, (2021), 13.8 : 1292.
6. Digiacomo L., et al., Journal of Nanotheranostics, (2021), 2(2), 82-93.
7. Digiacomo L., et al., Nanoscale Advances, (2021), 3(13), 3824-3834.
8. Vulpis E., et al., Molecular Pharmaceutics, (2021), 18.6: 2448-2453.
9. Perini G., et al., Pharmaceutics, (2021), 13(3), 378.

10. Digiacomo L., et al., Biointerphases, (2021), 16(1), 011010.
11. Palchetti S., et al., Biochimica et Biophysica Acta (BBA)-Biomembranes, (2020), 1862(3),183159.
12. Giulimondi F., et al., Nature communications, (2019), 10(1), 1-11.
13. Papi M., et al., Nanoscale, (2019), 11(32), 15339-15346.
14. Digiacomo L., et al., Lab on a Chip, (2019), 19(15), 2557-2567.
15. Digiacomo L., et al., Nanoscale Advances, (2019), 1(7), 2518-2522.
16. Mori M., et al., Scientific Reports, (2017), vol. 7.1: 1-13.

PATENT APPLICATIONS

[2016] Palermo R,Mori M,Tottone L,Ghirga F,Zhdanovskaya N,Ingallina C,Giulimondi F,Quaglio D,Botta B,Screpanti I. Inibitori di Notch per uso nel trattamento della leucemia linfoblastica acuta a cellule T. Italian Patent application number:102016000132360

HONOURS AND AWARDS

- | | |
|--------|---|
| [2021] | Progetto Avvio alla Ricerca, Tipo 2,
Sapienza, University of Rome
Project title: "Exploiting nanoparticle-protein corona for early cancer detection",
Number of protocol: AR22117A768C4B6B |
| [2022] | Borsa di studio Italy Post-Doc 2022 AIRC ID 28022 – Three-years fellowship "Michele e Carlo Ardizzone" |

Roma, 3/04/2023

Francesca Giulimondi Firmato